Radius

LONG LIVE TYMLOS!!!

 

Better yet- go back to your trailer and take your meds.

 

Ha! start up... micromanaging, report wanting, equo tracking, 8 calls per day wanting, start up.

 

We don't have any of that bullshit in our district, the Radius way is great!!

 

Consider yourself very, very lucky. I left an amazing manager, to come to this. Worst mistake of my career for sure. Definitely keeping my ears, and eyes open for other opportunities now. Reading through all of these comments... I wouldn't be surprised if one or 2 of you aren't from my region. It's absolutely miserable. There's no "Radius Way" going on here either.

 

Im in the west and I love the ASD. She is great

 

And I love my manager in Miami

 

Hilarious!

 

I haven't heard anything good about her. Met her as well at the national sales meeting, and she's a a piece of work. You're the first to say you "love" her. You must be one of her buddies. Like most women managers, they feel they have something to prove. So they become control freaks and try to micro manage thenshit out of you. It's their way or no way. God forbid if you actually know more than them. (I'd like to add, I'm a woman and saying women bosses are horrible MOST of the time)

 

And I'm willing to bet you are just a 'day at the beach' based on this post.

 

I wish I was at the beach. Maybe I can get transferred. Lots of openings around.

 

Haha!!! Hot off the press.... BUH-BYE Radius. Oh, wait... maybe Jesper is going to turn things around. He's the "commercial" guy. Since Bob wasn't capable of, right? Atleast, those are the lies we are told. Smh.

https://seekingalpha-com.cdn.ampproject.org/c/s/seekingalpha.com/amp/article/4100614-six-non-commercial-stage-healthcare-stocks-valued-high-part-ii

 

Hilarious indeed. The ASD in the West is bad enough, but the manager in Miami? OMG!

 

Can't speak to Miami, but west ASD is great, so go troll somewhere else

 

This company totally sucks. Massively messed up and I am so looking for a new job. Anyone who thinks otherwise is on drugs...lol

 

What's so bad about getting paid six figures to walk in 5-6 offices a day and ask them to write an amazing drug that's covering over 100 million lives? With a co-pay of $500 for their Medicare. Surely a Medicare patient can afford that? If they can't, they too need to get a job. I need scripts.

 

Yea, do tell what's so horrible. Management wants to know.

 

The writing is on the wall. Didn't even need to read this article to figure that out.

 

Radius Health, Inc. - At $1.59bn market cap, one would expect RDUS to have a clear run towards a target of strong revenue. That is not the case. Although it recently got approval for Tymos or abaloparatide-SC in the US, there are a number of problems here. First, the US approval has gone through, but the EU approval is having some hiccups. Second, closest competition drug Forteo has osteosacroma warnings, and now so does Tymlos. Forteo will go off-patent very soon, so that's a very small runway for the drug before a price problem. Third, osteoporosis is a "slow" disease, meaning, patients can afford to wait a few months for a cheaper biosim version of a competing drug like Forteo. Third, there are a bunch of other treatments options, some good, some not so bad, that will compete with Tymlos. The good news is that one of these, romosozumab, which doesn't work as well as Tymlos, received a CRL on CV risks. The other good news is that close competition Prolia has major if rare safety issues. However, fourth, for the company overall, there's hardly anything in the pipeline that justifies the huge market cap. Its breast cancer drug didn't do well in an early trial, and there's not much besides that and abaloparatide in the pipeline. Finally, with a $300mn latest secondary offering, cash balance of less than $200mn as of now, and a cash burnrate of over $180mn, this company doesn't look very attractive to me. Only silver lining is that it is trading near its 52-week low, but I wonder if yesterday's offering will break that barrier. So, this stock probably should not be continuing in our watchlist much longer.